Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

3d rendered HIV Virus in Blood Stream in color background

Results from the RIVER (Research in Viral Eradication of HIV Reservoirs) study, the first ever randomised clinical trial to test the ‘kick and kill’ approach to curing HIV, were published in The Lancet this week. Although the results were not what the researchers hoped for, the study clearly highlights the new direction that HIV research is heading. The trial, funded by the Medical Research Council, was a major collaboration between Oxford University, Imperial College and the MRC Clinical Trials Unit and was run by CHERUB (Collaborative HIV Eradication of Reservoirs UK BRC), an NIHR cooperative of clinicians, researchers and patients working together to find a cure for HIV.

Researchers used the drug Vorinostat to try and wake up dormant HIV hiding in CD4 T Cells (the ‘kick’) in conjunction with vaccine-stimulated CD8 T cells to enact the ‘kill’. The vaccine had been made in Oxford by a team led by Prof Tomas Hanke. The aim was to see if they could reduce the amount of HIV in the ‘latent reservoir’ – the source of persistent, dormant HIV that means the infection can’t be cured and current therapy needs to be taken for life. Although there was evidence that each individual step had worked, the trial was unable to show an impact on the size of the HIV reservoir.

Professor John Frater of the Nuffield Department of Medicine is a senior author and the Oxford NIHR BRC lead for CHERUB commented: “It is clearly disappointing that we didn’t see the result we hoped for in RIVER, but this is a landmark moment in HIV research as it marks a new era of investment in major clinical trials testing novel approaches to achieve an HIV cure. Participant engagement was incredible – this was a complex study and yet almost no visits were missed, showing how engaged the community of those living with HIV are in this sort of research. For many people living with HIV, current antiretroviral therapy is life changing but can be linked with toxicity, resistance and stigma. There has always been an aspiration for an HIV cure and although this is still a long way off – as RIVER shows – our study demonstrates that there is engagement and momentum in the research community and hope for the millions living with HIV.”

Read the full paper, published in The Lancet

Similar stories

EAVI2020: The Quest for an HIV Vaccine

In this long read published to coincide with International AIDS Day, we explore how an international collaboration – of which the University of Oxford is a key partner – has boosted HIV vaccine research. We thank our partners at Imperial College London for allowing us to reproduce and abridge this article.

New SMRU building opened in Thailand to provide health care to marginalized populations

The inauguration of a new joint Shoklo Malaria Research Unit (SMRU) and Borderland Health Foundation (BHF) Building took place in Mae Ramat, Thailand, this week.

Smoking increases the risks of 56 diseases in Chinese adults

Smoking increases the risks of 56 diseases and kills more than one million adults in China each year from 22 different causes, according to new research published in The Lancet Public Health.

Success for Oxford researchers in The Genetics Society 2023 Awards

Researchers from Department of Physiology, Anatomy and Genetics, Radcliffe Department of Medicine and Nuffield Department of Population Health have been recgonised in The Genetics Society 2023 awards.

New Studentship honours Enzo Cerundolo

A new Studentship has been announced in memory of the late MRC HIU Director and MRC WIMM Group Leader.